Search companies

Live

DIMERIX LIMITED (ASX: DXB)

Health care · News and insights

Price unavailable

Latest DXB announcements

Dimerix Ex-Chair’s Options Face Earlier Exercise Deadline After Retirement

2026-11-05 · Health care

DXB: $0.210 +5.00% · MC: $120M

Former Dimerix director Mark Diamond holds 500,000 unlisted options, which may now be exercised by 30 October 2027 following his retirement; any options not exercised by then will lapse. The notice follows Dimerix’s recent report of a stronger cash position and progress in its clinical programs.

Updated 2026-11-05 16:38
Share
SourcesFinal Director's Interest Notice - MD
Comments

Dimerix Cash More Than Doubles as Licensing Payment and Funding Facility Bolster Trial Runway

2026-10-29 · Health care

DXB: $0.215 +4.88% · MC: $120M

Dimerix's cash rose to approximately $35 million at the end of September from $16 million three months earlier, after it received an approximately $14 million upfront licensing payment and drew $17 million from a $34 million funding facility. The company says it has sufficient funding to complete the pivotal ACTION3 trial of DMX-200 and continue advancing the Phase 2 trial of newly acquired kidney injury treatment DMX-652. The first patients have completed the ACTION3 treatment period and moved into follow-up, while Hugh Alsop has been appointed interim chair following Mark Diamond's retirement.

Updated 2026-10-29 11:36
Share
SourcesDimerix Quarterly Activities Report and Appendix 4C
Comments